^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lutrate (leuprorelin depot)

    Company:
    Lubrizol, PharmaMar
    Drug class:
    GnRH agonist
    Related drugs:
    over1year
    LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer. (PubMed, J Urol)
    In pts with high-risk BCR, enza + ADT and enza mono demonstrated a statistically significant and clinically meaningful improvement in MFS vs pbo + ADT. The safety profile of enza was consistent with results from previous clinical studies.
    P3 data • Journal
    |
    Xtandi (enzalutamide) • Eligard (leuprolide acetate) • Lutrate (leuprorelin depot) • apatorsen (OGX-427) • custirsen (OGX-011)
    almost4years
    Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study (clinicaltrials.gov)
    N=160 --> 0 | Trial completion date: Nov 2024 --> Jan 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2024 --> Jan 2021
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    ALB (Albumin)
    |
    Eligard (leuprolide acetate) • Erleada (apalutamide) • Firmagon (degarelix) • Lutrate (leuprorelin depot) • leuprolide acetate for depot suspension • Viadur (leuprorelin implant)